# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Raymond James analyst Steven Seedhouse upgrades Gilead Sciences (NASDAQ:GILD) from Market Perform to Outperform and announce...
RBC Capital analyst Brian Abrahams reiterates Gilead Sciences (NASDAQ:GILD) with a Sector Perform and maintains $74 price ta...
– First Phase 3 HIV Prevention Trial to Show Zero Infections –– Independent Data Monitoring Committee Recommended That Gilead S...